OHA Drinking Water Services
Contact Report Details |
|||
PWS ID: | OR41 01208 | ||
PWS Name: | IDLEWAY IMPROVEMENT DISTRICT | ||
Who Was Contacted and Phone: | Martha Glanz (541) 447-3236 | ||
Contact Date: | 07/27/2007 | ||
Contacted By: | WILSON, BOB (DWP) | ||
Contact Method/Location: | Office | ||
Assistance Type: | CIRCUIT RIDER ASSISTANCE | ||
Reasons: | N/A N/A |
||
Details: | SUMMARY: High Arsenic Compliance and Understanding DETAILS: On April 3, 2007 a compliance sample for arsenic taken from Entry Point B resulted in a level of 41 ppb which exceeds the new EPA standard of 10ppm. System has 3 active wells. Well 4 is on Entry Point B. I contacted Martha Glanz the HOA Secretary for more information. She mailed me a copy of all arsenic tests done in the past 4 years as well as flow data from each well. She requested help in evaluating their options for compliance. I called Ronald Smith their certified operator and learned that he has been researching costs and providers for central treatment utilizing activated alumni, so I told him that I would evaluate point-of-use options as well as the possibility of blending existing sources differently to achieve compliance. Smith said that he has been cutting back on Well #4 and is only operating it manually for about 45 minutes a day. Wells 5 and 3 go on and off together when the lower reservoir calls for water. Well 5 at 28 gpm and well 6 as 12gpm. Reviewed arsenic results and well production data. Reviewed EPA standard and guide. Called Martha to request a meeting to share findings. On July 10, I met with them and left them with recommendations regarding monitoring compliance a plan to consider for blending sources differently and comparisons of central vs. point of use treatment. Discussed need of DWP approval of plans. ACTION NEEDED: System should conduct quarterly sampling on EP-B and submit a compliance sample for EP-A. Since well 4 is only producing 5 percent of water currently being used, it could be taken off line and maintained as an emergency well. System should continue to research providers for both central and point of use treatment. |